Figure 4.
BaP metabolite and DNA adduct levels in human tissue organoids after BaP treatment. Gastric D95 and D88; (A,F,K), pancreatic D39 and D44; (B,G,L), kidney D50 and D21; (C,H,M), colon (D311 and D351; (D,I,N) and liver undifferentiated and differentiated (D4; (E,J,O) organoids were treated with the indicated BaP concentrations for 48 h. Vehicle controls (0.5% DMSO) were included (not shown). The formation of BaP-t-7,8-dihydrodiol (A–E) and BaP-tetrol-l-1 (F–J) was determined by HPLC analysis. Metabolite levels are presented as peak area relative to phenacetine (arbitrary units). dG-N2-BPDE adduct formation was quantified using LC-ESI-MS/MS (K–O). Results are shown as mean ± SD (n ≥ 3).